Cancer Research Breakthroughs Archives - Page 4 of 5 - NFCR

Cancer Research Breakthroughs

Duo of Oncology Vaccine Pioneers at the National Cancer Institute to Receive 2018 Annual Szent-Györgyi Prize for Progress in Cancer Research

  FOR IMMEDIATE RELEASE: February 15, 2018 CONTACT: Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@nfcr.org First Occasion for Award to Recognize Extraordinary Contributions in Cancer Prevention, Role of Vaccines BETHESDA, MD – The National Foundation for Cancer Research (NFCR) announced today that the 2018 Szent-Györgyi Prize…...

Read more

Genetic Marker Can Help Focus Prostate Cancer Therapies

CLEVELAND, OH — Two studies conducted by the Cleveland Clinic revealed how a testosterone-related genetic abnormality can help predict individual patient responses to specific prostate cancer therapies. The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized…...

Read more

New Compound Targets Metastatic Cancer Cells

​Scientists​ ​at​ ​Bar-Ilan​ ​University​ ​in​ ​Israel​ ​successfully​ ​targeted​ ​and​ ​rendered​ ​inert​ ​the​ ​enzyme that metastatic​ ​cancer​ ​cells​ ​need​ ​to​ ​survive​ ​in​ ​the​ ​body​ ​once​ ​they​ ​have​ ​left​ ​their​ ​host​ ​tumor.​ ​...

Read more

Dr. Jim Allison: Cancer Immunotherapy Pioneer

Szent-Györgyi Prize Winners: Then & Now The Szent-Györgyi Prize was established in honor of Nobel laureate Dr. Albert Szent-Györgyi, co-founder of NFCR, to recognize outstanding scientific achievement in the war against cancer. Ten years later, “ASG Winners: Then & Now” looks at these winners, their extraordinary contributions and how their discoveries have made possible new…...

Read more

Cancer May Metastasize Without Lymph Node Involvement

Cancer May Metastasize Without Lymph Node Involvement NFCR-funded research finds two distinct patterns of metastatic spread in human colorectal cancer (Bethesda, MD, July 13, 2017) Research by several leading scientists including Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and…...

Read more

FDA Approves First Cancer Drug Based on Genetics… Not Tumor Location

Just last week, the U.S. Food and Drug Administration approved the cancer medicine— Keytruda® (generic name pembrolizumab)— to treat cancers that have a specific genetic mutation or biomarker. This is the first time a cancer treatment has been approved based on a biomarker rather than the body location where the…...

Read more

Attacking Metastatic Tumors in the Brain

Targeting HER3 could cripple metastatic cancers that have spread to the brain. (Bethesda, MD, June 5, 2017) Rakesh Jain, PhD, Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind…...

Read more

Non-Invasive Liquid Biopsy Uncovers Key Information to Treat Cancer

A liquid biopsy can provide valuable insight into how to best fight cancer. This noninvasive diagnostic is particularly helpful for patients who cannot undergo a surgical biopsy or whose tumor sample has been exhausted. In the not-too-distant future, liquid biopsies may be used to guide cancer treatment decisions and even…...

Read more

NFCR’s Genomics Newsroom: New genes linked to increased risk of ovarian and brain cancer

What is “genomics”? Cancer develops when genetic material (DNA) becomes damaged or changed. We know some cancer causing genetic changes are acquired (i.e. smoking), while others are inherited. Studying cancer genomics explores the differences between cancer cells and normal cells. Advances in understanding how cancer behaves at a genomic and…...

Read more